Good question, seem they're not obligated to fill sec, cause they apply for it, due the trail they had, CEO was still good to answer my 2 e-mail i sent him . I wont bother him again cause i'm out of this stock with a lost og 50% I just wanted to share little bit of my DD that i found to put this in tread, cause there not no much information , because there having been flling for a wild
that what i think too, they didn't retired there share, and they didn't go bankrup as fare that i can see.. Don't buy or sell on my account... good luck
ACCU-BREAK Pharmaceuticals, Inc. & Strides Arcolab Limited Enter into a Worldwide Joint Venture to Develop Generic Pharmaceuticals Using ACCU-BREAK(TM) Technologies Pharmaceutical Writers / Business Editors
PLANTATION, Fla.& BANGALORE, India--(BUSINESS WIRE)--June 6, 2006-- ACCU-BREAK Pharmaceuticals, Inc. and Strides Arcolab Limited, one of India's largest manufacturers and exporters of pharmaceutical products, today announced the signing of a definitive agreement to set up a worldwide Joint Venture Company (JVC) to develop generic products using the patent pending ACCU-BREAK(TM) technologies. This will be accomplished through a NEWCO to be called ACCU-STRIDES, a 50:50 JVC. It is anticipated that the JVC will outsource from Strides an exclusive product pipeline of generic and ANDA products in finished dosage forms. It is also anticipated that the JVC will outsource from ACCU-BREAK Pharmaceuticals sales, marketing and distribution capabilities for the North American markets while Strides will provide sales, marketing and distribution capabilities for the rest of the world. The product dossiers developed for the JVC by Strides will be owned exclusively by the JVC.
ACCU-BREAK(TM) tablets are designed for maximal dose accuracy when split, as well as for ease of breaking and to provide an optimal dosage for the millions of patients who split the tablets.
Currently, Strides has a total of fourteen manufacturing plants worldwide including an FDA approved plant in Bangalore, India where the ACCU-BREAK products will be manufactured. It is expected that the products using the ACCU-BREAK technologies will be developed for regulatory submission worldwide beginning in FY 2007.
Lawrence Solomon, M.D., Chairman & CEO of ACCU-BREAK Pharmaceuticals, Inc. stated, "ACCU-BREAK tablets are "Simply Better(TM)" because they are "Made to be Broken(TM)" or taken intact. ACCU-BREAK products are designed to provide an unprecedented degree of dosage flexibility by allowing easy and very accurate tablet breaking when a partial dose is desired. ACCU-BREAK products will have important quality advantages over standard products and in addition will allow for cost savings."
Arun Kumar, Vice-Chairman and Group CEO of Strides stated, "The ACCU-BREAK - Strides JVC is a true reflection of the "Strides Value" partnership model. Using our niche manufacturing and product development skill sets, Strides will ramp-up the product pipeline to leverage various ACCU-BREAK technologies to create a worldwide specialty generic pharmaceutical company. We will work towards creating critical mass for the JVC and significant value to all stakeholders."
About ACCU-BREAK Pharmaceuticals, Inc.
ACCU-BREAK Pharmaceuticals, Inc. is a privately held pharmaceutical company engaged in bio-equivalent product development utilizing its patent pending ACCU-BREAK technologies. The Company also intends to make its technologies available for licensing.
About Strides Arcolab Limited
Strides Arcolab Limited, listed on the Indian National Stock Exchange (STAR), has a global presence in more than 50 countries. The company has factories in India, USA, Poland, Italy, Brazil and Mexico. The Company supplies pharmaceuticals to a number of geographic locations including Latin America, Europe, South East Asia, Africa and Australia, amongst other markets. The Indian manufacturing facilities for the regulated markets are approved by all major regulatory bodies such as USFDA, MHRA, TGA and MCC.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. All forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement related to product liability, patent protection, governmental investigations, and other legal proceedings; ACCU-BREAK's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals; and any changes in business, political, and economic conditions. ACCU-BREAK disclaims any responsibility to update any forward-looking statements.
KEYWORD: ASIA PACIFIC NORTH AMERICA FLORIDA UNITED STATES INDIA INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL MANUFACTURING CONTRACT/AGREEMENT SOURCE: ACCU-BREAK Pharmaceuticals, Inc.
News 
Market Data 
Discover 
AI
